6.7.7. second-line treatment mcrpc. patients receive treatment mcrpc eventually progress. treatment options setting presented table 6.7.3. high-level evidence exists second-line treatments first-line treatment mcrpc docetaxel arpi. paucity high-level data regards sequence treatments case pretreatment arpi and/or docetaxel mhspc. 6.7.7.1. cabazitaxel cabazitaxel taxane activity docetaxel-resistant cancers. studied large prospective, randomised, phase iii trial (tropic) comparing cabazitaxel plus prednisone vs. mitoxantrone plus prednisone 755 patients mcrpc, progressed docetaxel-based chemotherapy . patients received maximum ten cycles cabazitaxel (25 mg/m2) mitoxantrone (12 mg/m2) plus prednisone (10 mg/day). overall survival primary endpoint significantly longer cabazitaxel (median: 15.1 vs. 12.7 months, p < 0.0001). also significant improvement pfs (median: 2.8 vs. 1.4 months, p < 0.0001), objective recist response (14.4% vs. 4.4%, p < 0.005), psa response rate (39.2% vs. 17.8%, p < 0.0002). treatment-associated grade 3–4 aes developed significantly often cabazitaxel arm, particularly haematological (68.2% vs. 47.3%, p < 0.0002) also non-haematological (57.4 vs. 39.8%, p < 0.0002) toxicity. two post-marketing randomised phase iii trials, cabazitaxel shown superior docetaxel first-line setting; second-line setting terms os, 20 mg/m2 cabazitaxel inferior 25 mg/m2, less toxic. therefore, lower dose preferred . cabazitaxel preferably given prophylactic granulocyte colonystimulating factor (g-csf) administered physicians expertise handling neutropenia sepsis . 6.7.7.2. abiraterone acetate docetaxel positive results large phase iii trial (cou-aa-301) reported median follow-up 12.8 months confirmed final analysis . total 1,195 patients mcrpc randomised 2:1 aap placebo plus prednisone. patients progressive disease based prostate cancer clinical trials working group 2 (pcwg2) criteria docetaxel therapy (with maximum two previous chemotherapeutic regimens). primary endpoint os, planned hr 0.8 favour aap. median follow-up 20.2 months, median survival aap group 15.8 months compared 11.2 months placebo arm (hr: 0.74, p < 0.0001). benefit observed subgroups secondary objectives favour aap (psa, radiologic tissue response, time psa objective progression). incidence common grade 3–4 aes differ significantly arms, mineralocorticoid-related side effects frequent aap group, mainly grade 1–2 (fluid retention, oedema hypokalaemia). 6.7.7.3. enzalutamide docetaxel planned interim analysis affirm study published 2012 . trial randomised 1,199 patients mcrpc 2:1 fashion enzalutamide placebo. patients progressed docetaxel treatment, according pcwg2 criteria. corticosteroids mandatory, could prescribed, received 30% patients. primary endpoint os, expected hr benefit 0.76 favour enzalutamide. median follow-up 14.4 months, median survival enzalutamide group 18.4 months compared 13.6 months placebo arm (hr: 0.63, p < 0.001). led recommendation halt unblind study. benefit observed irrespective age, baseline pain intensity, type progression. final analysis longer follow-up os results confirmed despite crossover extensive post-progression therapies . enzalutamide active also patients visceral metastases. secondary objectives favour enzalutamide (psa, soft tissue response, qol, time psa, objective progression). difference terms side effects observed two groups, lower incidence grade 3–4 aes enzalutamide arm. 0.6% incidence seizures enzalutamide group compared none placebo arm. 6.7.7.4. radium-223 arpi arpi docetaxel bone-specific drug associated survival benefit α-emitter radium-223. large phase iii trial (alsympca) 921 patients symptomatic mcrpc, failed unfit docetaxel, randomised six injections 50 kbq/kg radium-223 placebo plus soc. primary endpoint os. radium-223 significantly improved median os 3.6 months (hr: 0.70, p < 0.001) also associated prolonged time first skeletal event, improvement pain scores improvement qol . associated toxicity mild and, apart slightly haematologic toxicity diarrhoea radium-223, differ significantly placebo arm . radium-223 effective safe whether patients docetaxel pre-treated . due safety concerns, use radium-223 restricted docetaxel least one ar targeted agent . particular, use radium-223 combination aap showed significant safety risks related fractures deaths. striking patients without concurrent use bone health agents radium-223 always used together bone health agents (see chapter 6.7.11.2) 6.7.7.5. rucaparib arpi 2:1 randomised, controlled, phase iii trial (triton-3) 405 mcrpc patients included. patients selected brca1, brca2, atm alteration disease progression treatment arpi mcrpc. treatment follows: rucaparib 600 mg twice daily physician’s choice control, either second line docetaxel arpi given previously. first endpoint rpfs intention-to-treat group significantly better rucaparib (median, 10.2 months 6.4 months, respectively; hr 0.61; 95% ci, 0.47 0.80; p<0.001). small atm subgroup derive abenefit. interim analysis revealed os immature. study designed allowed cross-over 60% patients received parp inhibitor progression (47% rucaparib). regards control arms, median rpfs longer rucaparib docetaxel (11.2 months vs. 8.3 months; hazard ratio, 0.53; 95% ci, 0.37 0.77) also longer arpi (11.2 months vs. 4.5 months; hazard ratio, 0.38; 95% ci, 0.25 0.58). frequent adverse events rucaparib fatigue, nausea anemia, including 24% grade ≥3 anemia 29% patients rucaparib required least one blood transfusion . rucaparib approved fda. 6.7.7.6. olaparib arpi (see chapter 6.7.8.3 parp inhibitors mcrpc)